Pomerantz Law Firm Launches Investigation into XOMA Amid Phase 3 Setback

Shareholder Concerns Escalate as Phase 3 Trial Misses Key Endpoints

XOMA Royalty Corporation (NASDAQ: XOMA) is now under the investigative lens of Pomerantz LLP, with the law firm probing potential claims against the company and its management. This cautious move comes shortly after Rezolute, Inc.—a development partner of XOMA—revealed disappointing top-line results from its pivotal Phase 3 sunRIZE study for ersodetug in congenital hyperinsulinism patients. The trial failed to meet both its primary and key secondary endpoints, and any observed improvements did not achieve statistical significance versus placebo.

Stock Price Remains Under Pressure After Steep December Drop

After the December 11th news from Rezolute, XOMA shares dropped sharply, tumbling 22.76% to close at $25.39 on December 19, 2025. As of 10:32 AM today, XOMA trades at $28.16, down another 2.19% intraday. This continuing weakness highlights lingering anxiety among investors as the market digests both clinical trial disappointment and the new layer of legal scrutiny. A data snapshot below puts XOMA’s recent stock performance in perspective:

Ongoing Legal Action and What’s at Stake for Investors

The Pomerantz investigation will explore whether XOMA and certain officers or directors may have engaged in securities fraud or other unlawful business practices in light of the trial results and their disclosure. While the press release is careful not to allege wrongdoing yet, it signals an increased risk of shareholder litigation and potentially heightened regulatory scrutiny. The class action claims process—if it proceeds—gives investors a formal channel to seek redress for financial losses linked to corporate missteps.

Takeaway: Increased Uncertainty, More Questions Than Answers

For XOMA shareholders, the dual blow of a failed clinical trial and potential legal challenge introduces a phase of heightened uncertainty. How XOMA addresses investor concerns in the wake of these events—and whether management can restore confidence—remain open questions. Investors may wish to monitor upcoming company statements and legal developments closely before making major portfolio decisions.

Contact Information:

If you have feedback or concerns about the content, please feel free to reach out to us via email at support@marketchameleon.com.

About the Publisher - Marketchameleon.com:

Marketchameleon is a comprehensive financial research and analysis website specializing in stock and options markets. We leverage extensive data, models, and analytics to provide valuable insights into these markets. Our primary goal is to assist traders in identifying potential market developments and assessing potential risks and rewards.

NOTE: Stock and option trading involves risk that may not be suitable for all investors. Examples contained within this report are simulated and may have limitations. Average returns and occurrences are calculated from snapshots of market mid-point prices and were not actually executed, so they do not reflect actual trades, fees, or execution costs. This report is for informational purposes only, and is not intended to be a recommendation to buy or sell any security. Neither Market Chameleon nor any other party makes warranties regarding results from its usage. Past performance does not guarantee future results. Please consult a financial advisor before executing any trades. You can read more about option risks and characteristics at theocc.com.

The information is provided for informational purposes only and should not be construed as investment advice. All stock price information is provided and transmitted as received from independent third-party data sources. The Information should only be used as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments and trading strategies. The Company does not guarantee the accuracy, completeness or timeliness of the Information.

Disclosure: This article was generated with the assistance of AI